Biomarker Analysis in BO21015, a Phase II Randomized Study of First-line Bevacizumab (BEV) Combined with Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC)
Invited conference paper presented and published in conference proceedings

香港中文大學研究人員

全文

其它資訊
著者MOK Shu Kam Tony, GORBUNOVA V, JUHASZ E, SZIMA B, BURDAEVA O, YU Cj, DELMAR P, PALLAUD C, JONNAERT M, RECK M
會議名稱The European Journal of Cancer 16th ECCO
會議國家/地區英國
會議論文集題名The European Journal of Cancer 16th ECCO
詳細描述organized by The 2011 European Multidisciplinary Cancer Congress,
出版年份2011
月份9
出版地United Kingdom
頁次1
語言英式英語
關鍵詞BO21015; NSCLC

上次更新時間 2018-20-01 於 07:49